Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REGN7544 in Sepsis-Induced Hypotension
2024-514946-35-00Phase 2Completed
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Feb 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 3
01
Overview
Phase 2, randomised, double-blind trial in sepsis comparing REGN7544 with REGN7544 Matching Placebo (2 arms). Primary endpoint: Cumulative vasopressor dose. Started Feb 2025; status: completed.
02
Drugs
baloncibart
03
Conditions
sepsis
Beyond the preview
Go deeper on 2024-514946-35-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514946-35-00.